GlassScriptPhysician profile
Katherine Tbaba
NPI 1033846654
$1,618.14
in general payments reported to CMS, 2019-2025
26 companies · $329 in 2025
The $329 reported for 2025 was more than what 87% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $11.77 · 2023: $678 · 2024: $599 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $199.61 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Novocure INC. | $170.87 | 2023 | Optune |
| Takeda Pharmaceuticals U.S.A., INC. | $141.13 | 2024-2025 | Fruzaqla, Iclusig |
| Incyte Corporation | $140.69 | 2023-2024 | Pemazyre, Jakafi |
| Abbvie INC. | $140.43 | 2024-2025 | |
| Cti Biopharma Corp. | $121.94 | 2023 | Vonjo |
| Glaxosmithkline, LLC. | $91.47 | 2023-2025 | Jemperli, Zejula, Bexsero |
| Neurocrine Biosciences, INC. | $81.21 | 2025 | |
| Novartis Pharmaceuticals Corporation | $75.97 | 2024 | |
| Pfizer INC. | $73.02 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $39.86 | 2024-2025 | Libtayo |
| Foundation Medicine, INC. | $34.68 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.10 | 2023 | |
| Emmaus Medical, INC. | $26.12 | 2023 | Endari |
| Janssen Biotech, INC. | $25.81 | 2023 | Erleada |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $25.21 | 2024 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $24.97 | 2024 | Imfinzi |
| Servier Pharmaceuticals LLC | $24.84 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $22.99 | 2024 | Akynzeo |
| Tris Pharma INC | $22.19 | 2023 | Dyanavel Xr |
| Genentech USA, INC. | $19.77 | 2024 | Tecentriq |
| Cranial Technologies, INC | $19.27 | 2023 | Doc Band |
| Adc Therapeutics America, INC. | $19.08 | 2024 | |
| Morphosys, US INC. | $18.15 | 2023 | Monjuvi |
| Amgen INC. | $12.99 | 2023 | Kyprolis, Blincyto |
| Supernus Pharmaceuticals, INC. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Tbaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.